Skip to main
  1. Stocks
  2. Adaptive Biotechnologies
  3. Forecast
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is benefiting from a stronger clinical and reimbursement backdrop for clonoSEQ, with NCCN’s updated multiple myeloma guidelines explicitly naming it as the only FDA-cleared NGS MRD assay and expanding testing frequency, which should support materially higher utilization. The company also posted solid operating momentum, including Q2’26 revenue of $72M, MRD revenue of $66M, MRD volumes up 43% year over year, and adjusted EBITDA of -$0.7M, while management raised 2026 MRD revenue guidance to $268M-$278M. Longer term, its dominant position in a still underpenetrated heme MRD market, rising ASPs toward $1,400 in 2026 and $1,700-$1,800 over time, improving gross margins, and the planned separation of MRD from Immune Medicine all support a favorable fundamental outlook.

Bears say

Adaptive Biotechnologies is facing a negative fundamental setup because its core MRD growth depends on successful EMR integrations and broader community adoption, both of which could lag expectations and slow volume expansion. Competition is also a meaningful risk as more players may enter the under-penetrated heme market, while reimbursement, clinical guideline hurdles, and slower-than-expected customer adoption or product launches could further limit uptake of clonoSEQ. In addition, the Immune Medicine business may exceed burn targets and strain resources needed for MRD growth, and the planned separation by YE'26 is uncertain in timing and outcome despite the stock trading at a significant premium multiple.

Adaptive Biotechnologies (ADPT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction

Get the latest Adaptive Biotechnologies (ADPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Adaptive Biotechnologies (ADPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 7 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Adaptive Biotechnologies (ADPT) Analyst Forecast & Price Prediction

Get the latest Adaptive Biotechnologies (ADPT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Adaptive Biotechnologies (ADPT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ADPT stock data and trends